Therefore, the interplay between SIX1, EMT, and CSCs must be considered in future investigations, particularly in the context of mechanisms governing the effects of SIX1 on breast cancer pathobiology, with the goal of identifying new therapeutic targets for breast cancer patients [46, 48]. The gene discussed is SIX1; the disease is breast carcinoma.